Drug intelligence / Profile preview

IL2 fusion toxin

Development stage: Preclinical
Lead developer: University of Colorado Anschutz Medical Campus
Modality: Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

IL2 fusion toxin is a diphtheria toxin-based recombinant human interleukin-2 (IL2) fusion toxin. It was developed as an Ontak®-like therapeutic using a diphtheria toxin-resistant yeast Pichia pastoris expression system. This drug is designed to target cells expressing CD25, a cell-surface marker highly expressed in certain types of cutaneous T-cell lymphomas (CTCL).

Other names: Ontak-like human IL2 fusion toxin

Targets

IL2RA (Interleukin-2 receptor alpha subunit)

Beyond the preview

Go deeper on IL2 fusion toxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL2 fusion toxin.

Explore the full profile